204 related articles for article (PubMed ID: 28797967)
21. Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission.
Jiang Y; Cao S; Bright DK; Bever AM; Blakney AK; Suydam IT; Woodrow KA
Mol Pharm; 2015 Dec; 12(12):4363-74. PubMed ID: 26529558
[TBL] [Abstract][Full Text] [Related]
22. Antiviral and immunological effects of tenofovir microbicide in vaginal herpes simplex virus 2 infection.
Vibholm L; Reinert LS; Søgaard OS; Paludan SR; Østergaard L; Tolstrup M; Melchjorsen J
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1404-11. PubMed ID: 22867119
[TBL] [Abstract][Full Text] [Related]
23. Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection.
Mesquita PM; Rastogi R; Segarra TJ; Teller RS; Torres NM; Huber AM; Kiser PF; Herold BC
J Antimicrob Chemother; 2012 Jul; 67(7):1730-8. PubMed ID: 22467632
[TBL] [Abstract][Full Text] [Related]
24. Multipurpose Prevention Approaches with Antiretroviral-Based Formulations.
Jean-Pierre N; Barnable P; Kizima L; Rodríguez A; Seidor S; Cooney ML; Clark MR; Doncel GF; Robbiani M; Zydowsky TM; Teleshova N; Fernández-Romero JA
Antimicrob Agents Chemother; 2016 Feb; 60(2):1141-4. PubMed ID: 26596943
[TBL] [Abstract][Full Text] [Related]
25. A New Approach to Developing Long-Acting Injectable Formulations of Anti-HIV Drugs: Poly(Ethylene Phosphoric Acid) Block Copolymers Increase the Efficiency of Tenofovir against HIV-1 in MT-4 Cells.
Nifant'ev I; Siniavin A; Karamov E; Kosarev M; Kovalchuk S; Turgiev A; Nametkin S; Bagrov V; Tavtorkin A; Ivchenko P
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396968
[TBL] [Abstract][Full Text] [Related]
26. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC
AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514
[TBL] [Abstract][Full Text] [Related]
27. In vitro Study on Synergistic Interactions Between Free and Encapsulated Q-Griffithsin and Antiretrovirals Against HIV-1 Infection.
Minooei F; Fried JR; Fuqua JL; Palmer KE; Steinbach-Rankins JM
Int J Nanomedicine; 2021; 16():1189-1206. PubMed ID: 33623382
[TBL] [Abstract][Full Text] [Related]
28. Nanoparticles-in-film for the combined vaginal delivery of anti-HIV microbicide drugs.
Cunha-Reis C; Machado A; Barreiros L; Araújo F; Nunes R; Seabra V; Ferreira D; Segundo MA; Sarmento B; das Neves J
J Control Release; 2016 Dec; 243():43-53. PubMed ID: 27664327
[TBL] [Abstract][Full Text] [Related]
29. Electrospun fibers for vaginal anti-HIV drug delivery.
Blakney AK; Ball C; Krogstad EA; Woodrow KA
Antiviral Res; 2013 Dec; 100 Suppl():S9-16. PubMed ID: 24188701
[TBL] [Abstract][Full Text] [Related]
30. The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro.
Alteri C; Surdo M; Di Maio VC; Di Santo F; Costa G; Parrotta L; Romeo I; Gori C; Santoro MM; Fedele V; Carta S; Continenza F; Pinnetti C; Bellagamba R; Liuzzi G; Orchi N; Latini A; Bertoli A; Girardi E; Alcaro S; Giuliani M; Petrosillo N; Andreoni M; Antinori A; Monforte AD; Ceccherini-Silberstein F; Artese A; Perno CF; Svicher V
J Glob Antimicrob Resist; 2016 Dec; 7():1-7. PubMed ID: 27530997
[TBL] [Abstract][Full Text] [Related]
31. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.
Stray KM; Park Y; Babusis D; Callebaut C; Cihlar T; Ray AS; Perron M
Antiviral Res; 2017 Apr; 140():116-120. PubMed ID: 28131805
[TBL] [Abstract][Full Text] [Related]
32. An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate.
Baum MM; Butkyavichene I; Churchman SA; Lopez G; Miller CS; Smith TJ; Moss JA
Int J Pharm; 2015 Nov; 495(1):579-587. PubMed ID: 26386138
[TBL] [Abstract][Full Text] [Related]
33. Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release.
Giesler KE; Liotta DC
J Med Chem; 2016 Nov; 59(22):10244-10252. PubMed ID: 27933889
[TBL] [Abstract][Full Text] [Related]
34. Biophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application.
Ramanathan R; Jiang Y; Read B; Golan-Paz S; Woodrow KA
Acta Biomater; 2016 May; 36():122-31. PubMed ID: 26947382
[TBL] [Abstract][Full Text] [Related]
35. Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures.
Blakney AK; Krogstad EA; Jiang YH; Woodrow KA
Int J Nanomedicine; 2014; 9():2967-78. PubMed ID: 24971008
[TBL] [Abstract][Full Text] [Related]
36. Manufacturing scale-up of electrospun poly(vinyl alcohol) fibers containing tenofovir for vaginal drug delivery.
Krogstad EA; Woodrow KA
Int J Pharm; 2014 Nov; 475(1-2):282-91. PubMed ID: 25169075
[TBL] [Abstract][Full Text] [Related]
37. Poly (4-styrenesulfonic acid-co-maleic acid) is an entry inhibitor against both HIV-1 and HSV infections - potential as a dual functional microbicide.
Qiu M; Chen Y; Song S; Song H; Chu Y; Yuan Z; Cheng L; Zheng D; Chen Z; Wu Z
Antiviral Res; 2012 Nov; 96(2):138-47. PubMed ID: 22940611
[TBL] [Abstract][Full Text] [Related]
38. Rapid-Release Griffithsin Fibers for Dual Prevention of HSV-2 and HIV-1 Infections.
Tyo KM; Lasnik AB; Zhang L; Jenson AB; Fuqua JL; Palmer KE; Steinbach-Rankins JM
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32229493
[TBL] [Abstract][Full Text] [Related]
39. Preparation, characterization, and safety evaluation of poly(lactide-co-glycolide) nanoparticles for protein delivery into macrophages.
Guedj AS; Kell AJ; Barnes M; Stals S; Gonçalves D; Girard D; Lavigne C
Int J Nanomedicine; 2015; 10():5965-79. PubMed ID: 26445538
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
